Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134]

Haichuan Wang¹, Shanshan Zhang², Yi Zhang², Jiaoyuan Jia³, Jingxiao Wang⁴, Xianqiong Liu⁵, Jie Zhang⁶, Xinhua Song², Silvia Ribback⁷, Antonio Cigliano⁸, Matthias Evert⁸, Bingyong Liang⁹, Hong Wu¹⁰, Diego F Calvisi¹¹, Yong Zeng¹², Xin Chen¹³

Affiliations

¹ Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
² Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
³ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Department of Oncology and Hematology, the Second Hospital, Jilin University, Changchun, China.
⁴ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
⁵ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei, China.
⁶ Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
⁷ Institute of Pathology, University of Greifswald, Greifswald, Germany.
⁸ Institute of Pathology, University of Regensburg, Regensburg, Germany.
⁹ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
¹⁰ Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
¹¹ Institute of Pathology, University of Regensburg, Regensburg, Germany. Electronic address: diego.calvisi@klinik.uni-regensburg.de.
¹² Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zengyong@medmail.com.cn.
¹³ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA. Electronic address: xin.chen@ucsf.edu.

PMID: 34965902
PMCID: PMC10508224
DOI: 10.1016/j.jhep.2021.12.006

Published Erratum

Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134]

Haichuan Wang et al. J Hepatol. 2022 Mar.

. 2022 Mar;76(3):755-756.

doi: 10.1016/j.jhep.2021.12.006. Epub 2021 Dec 26.

Authors

Affiliations

¹ Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
² Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
³ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Department of Oncology and Hematology, the Second Hospital, Jilin University, Changchun, China.
⁴ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
⁵ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei, China.
⁶ Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
⁷ Institute of Pathology, University of Greifswald, Greifswald, Germany.
⁸ Institute of Pathology, University of Regensburg, Regensburg, Germany.
⁹ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
¹⁰ Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
¹¹ Institute of Pathology, University of Regensburg, Regensburg, Germany. Electronic address: diego.calvisi@klinik.uni-regensburg.de.
¹² Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zengyong@medmail.com.cn.
¹³ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA. Electronic address: xin.chen@ucsf.edu.

PMID: 34965902
PMCID: PMC10508224
DOI: 10.1016/j.jhep.2021.12.006

No abstract available

PubMed Disclaimer

Figures

**Fig. 1.. Activation of the YAP/TAZ cascade in c-Myc driven HCC in mice.**
(A) Western blotting results of LAST1, LATS2, and YAP/TAZ expression in the NL and c-Myc HCC tissues (T). (B) mRNA expression of *Ctgf* and *Cyr61.* (C) Western blotting results of nuclear YAP (n-YAP) and nuclear TAZ (n-TAZ) levels. Histone H3 and β-Tubulin were used as nuclear and cytoplasmic (Cyto) protein loading controls, respectively. (D) Quantification of nuclear YAP (n-YAP) and nuclear Taz (n-TAZ) levels. (E) *Yap* and *Taz* (*Wwtr1*) mRNA relative expression in NL and T tissues. N = 4 biological replicates for each group. (F) Representative immunohistochemistry of a c-Myc mouse tumor lesion (T) exhibiting robust nuclear immunoreactivity for c-MYC and TAZ, whereas only a few tumor cells display nuclear staining for YAP. Scale bar: 100 μm. (B, D, E) Mean ± SD; Unpaired t test, Welch’s t test or Mann-Whitney test. HCC, hepatocellular carcinoma; NL, normal liver; T, tumor.

See this image and copyright information in PMC

Erratum for

TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H, Zhang S, Zhang Y, Jia J, Wang J, Liu X, Zhang J, Song X, Ribback S, Cigliano A, Evert M, Liang B, Wu H, Calvisi DF, Zeng Y, Chen X. Wang H, et al. J Hepatol. 2022 Jan;76(1):123-134. doi: 10.1016/j.jhep.2021.08.021. Epub 2021 Aug 28. J Hepatol. 2022. PMID: 34464659 Free PMC article.

Publication types

Actions

Grants and funding

P30 DK026743/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134]

Affiliations

Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134]

Authors

Affiliations

Figures

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources